Ras Al Khaimah, United Arab Emirates: ME NewsWire: Julphar Gulf Pharmaceutical Industries, the largest generic pharmaceutical company in Middle East and North Africa (MENA), has launched PULSE – the first research application in the region to study behaviors and attitudes in disease management, during a launch event that took place at the Park Hyatt hotel in Dubai on September 30th 2016.
PULSE – available on iOS and Android – will support Julphar in studying key therapeutic aspects starting by studying trends in management of dyslipidemia in the region – focusing on its prevalence, clinical practices and treatment – by submitting a medical study in its first phase to 30 selected practitioners on their current practices and patient-centered management of dyslipidemia. The new and one-of-a-kind mobile approach of the study will make it easier for the selected physicians to participate and to provide the most relevant inputs.
“We are proud to be the first company to penetrate this field of advanced mobile technology in the region, The study is part of Julphar’s continuous efforts to help the medical community better understand the compelling challenges in the cardiovascular field, and will support us in joining forces with the healthcare professionals (HCPs) to find out an appropriate and dedicated solution to face those challenges,” said Dr Hosam Badr, Marketing Director at Julphar. “The study will also help reduce the gap that exists among HCPs between medical standardized procedures and reality.”
The roll-out phase of the study, initially targeting physicians from UAE, is expected to expand throughout the region in the near future.
Established in 1980, Julphar is the largest generic pharmaceutical manufacturer in Middle East and North Africa, producing over 200 branded products across its fifteen manufacturing facilities. Julphar’s mission is to offer high quality medicines at affordable prices, and its product portfolio includes: Wound, Anemia and Women Care, Adult Primary Care, Pediatric Primary Care, Gastro Care and Pain Management, Cardiopulmonary Care, and Consumer Care. In 2012 Julphar launched Julphar Diabetes, a 150 million-dollar Active Pharmaceutical Ingredient (API) manufacturing facility that has the capacity to produce 1,500 kg of recombinant human insulin and insulin analogues crystals (rDNA). Julphar employs approximately 3,000 people around the world and registered sales revenue of AED 1.47 billion in the year ending 2015.